Monoclonal antibodies (mAbs) are the active proteins representing many biologics and biosimilars on the market in 2024. Several human conditions have been treated through the use of commercial mAbs such as cancer, osteoporosis, and COVID-19 . Oncological drugs such as trastuzumab (2), bevacizumab (3), and rituximab have each seen manufacturing increases in recent years due to proven drug effectiveness and loss of patented biologic drug exclusivity .